Goldman Sachs Maintains Agilon Health Buy Recommendation

Fintel reports that on August 15, 2023, Goldman Sachs maintained coverage of Agilon Health (NYSE:AGL) with a Buy recommendation.

Analyst Price Forecast Suggests 57.09% Upside

As of August 2, 2023, the average one-year price target for Agilon Health is 29.34. The forecasts range from a low of 18.18 to a high of $43.05. The average price target represents an increase of 57.09% from its latest reported closing price of 18.68.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Agilon Health is 3,950MM, an increase of 7.63%. The projected annual non-GAAP EPS is -0.01.

What is the Fund Sentiment?

There are 512 funds or institutions reporting positions in Agilon Health. This is an increase of 29 owner(s) or 6.00% in the last quarter. Average portfolio weight of all funds dedicated to AGL is 0.41%, an increase of 6.62%. Total shares owned by institutions increased in the last three months by 17.05% to 594,531K shares. The put/call ratio of AGL is 0.34, indicating a bullish outlook.

What are Other Shareholders Doing?

Clayton, Dubilier & Rice holds 194,611K shares representing 48.00% ownership of the company. No change in the last quarter.

Capital World Investors holds 42,436K shares representing 10.47% ownership of the company. In it’s prior filing, the firm reported owning 37,918K shares, representing an increase of 10.65%. The firm increased its portfolio allocation in AGL by 59.68% over the last quarter.

Wellington Management Group Llp holds 38,157K shares representing 9.41% ownership of the company. In it’s prior filing, the firm reported owning 20,346K shares, representing an increase of 46.68%. The firm decreased its portfolio allocation in AGL by 81.56% over the last quarter.

ANEFX – NEW ECONOMY FUND holds 17,247K shares representing 4.25% ownership of the company. In it’s prior filing, the firm reported owning 14,503K shares, representing an increase of 15.91%. The firm increased its portfolio allocation in AGL by 5.40% over the last quarter.

T. Rowe Price Investment Management holds 14,593K shares representing 3.60% ownership of the company. In it’s prior filing, the firm reported owning 2,684K shares, representing an increase of 81.60%. The firm increased its portfolio allocation in AGL by 277.07% over the last quarter.

Agilon Health Background Information
(This description is provided by the company.)

agilon health is transforming healthcare by empowering community-based physicians with the resources and expertise they need to innovate the payment and delivery of care for seniors. agilon health enables physicians to create their own Medicare-centric globally capitated line of business. The agilon Total Care Model is powered by its purpose-built platform and enabled through a growing national network of like-minded physician partners. With agilon, physicians are freed from the constraints of the transactional fee-for-service reimbursement model and are able to practice team-based, coordinated care to serve the individual needs of their senior patients and to transition to a sustainable and predictable, long-term business model. The rapidly growing appeal of the agilon platform, partnership model and network of leading community-based physicians has allowed the company to expand to 17 local communities with 16 anchor physician groups, as well as a network of physicians across Hawaii, in fewer than five years.

This article originally appeared on Fintel